Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Xavier Poiré,
Myriam Labopin,
Emmanuelle Polge,
Jakob Passweg,
Charles Craddock,
Didier Blaise,
Jan J. Cornelissen,
Liisa Volin,
Nigel H. Russell,
Gérard Socié,
Mauricette Michallet,
Nathalie Fegueux,
Patrice Chevallier,
Arne Brecht,
Mathilde Hunault-Berger,
Mohamad Mohty,
Jordi Esteve,
Arnon Nagler
Affiliations
Xavier Poiré
Section of Hematology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
Myriam Labopin
Acute Leukemia Working Party of the EBMT;Service d’Hématologie, Hôpital Saint-Antoine, Paris, France
Emmanuelle Polge
Acute Leukemia Working Party of the EBMT;Service d’Hématologie, Hôpital Saint-Antoine, Paris, France
Jakob Passweg
Hematology, University Hospital, Basel, Switzerland
Charles Craddock
Center for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK
Didier Blaise
Programme de Transplantation et Thérapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, France
Jan J. Cornelissen
Daniel den Hoed Cancer Centre, Erasmus Medical Center, Rotterdam, the Netherlands
Liisa Volin
Stem Cell Transplantation Unit, HUH Comprehensive Cancer Center, Helsinki, Finland
Nigel H. Russell
Nottingham City Hospital, UK
Gérard Socié
Department of Hematology, Hôpital Saint-Louis, Paris, France
Mauricette Michallet
Service Hématologie, Centre Hospitalier Lyon Sud, France
Nathalie Fegueux
Département d’Hématologie Clinique, CHU Lapeyronie, Montpellier, France
Patrice Chevallier
Département d’Hématologie, CHU Nantes, France
Arne Brecht
Deutsche Klinik für Diagnostik, KMT Zentrum, Wiesbaden, Germany
Mathilde Hunault-Berger
Service des Maladies du Sang, CHRU, Angers, France
Mohamad Mohty
Acute Leukemia Working Party of the EBMT;Service d’Hématologie, Hôpital Saint-Antoine, Paris, France
Intermediate-risk cytogenetic acute myeloid leukemia with an internal tandem duplication of FLT3 (FLT3-ITD) is associated with a high risk of relapse, and is now a standard indication for allogeneic stem cell transplantation. Nevertheless, most studies supporting this strategy have been performed in young patients. To address the benefit of allogeneic transplantation in the elderly, we made a selection from the European Society for Blood and Marrow Transplantation registry of de novo intermediate-risk cytogenetic acute myeloid leukemia harboring FLT3-ITD in patients aged 60 or over and transplanted from a related or unrelated donor between January 2000 and December 2015. Two hundred and ninety-one patients were identified. Most patients received a reduced-intensity conditioning (82%), while donors consisted of an unrelated donor in 161 (55%) patients. Two hundred and twelve patients received their transplantation in first remission, 37 in second remission and 42 in a more advanced stage of the disease. The 2-year leukemia-free survival rate was 56% in patients in first remission, 22% in those in second remission and 10% in patients with active disease, respectively (P
